Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Li-Yao Huang

Postdoctoral researcher

Background

I completed my DPhil study in the laboratory of Prof. Catherine Pears at the University of Oxford in 2020.  My DPhil research focused on the role of H3K4me3-directed histone 3 acetylation (H3Ac) in the mechanism of action of TSA, a histone deacetylase inhibitor (HDACi). HDACis are approved for the treatment of multiple myeloma and T-cell lymphoma. However, the response rate was only ~30% and drug resistance emerged post-treatment. HDACi treatment leads to hyperacetylation of histone H3 that favours those with H3K4me3 mark, but the biological importance of this dynamic acetylation is unknown. Using Dictyostelium as a model organism, I revealed that mutations leading to loss of H3K4me3 confer loss of rapid H3 hyperacetylation and result in resistance to TSA during development. Using genetic, biochemical and cell-based assays I also unravelled Sgf29, a subunit of in the large SAGA acetyltransferase complex, as the mediator of H3K4me3-directed H3Ac.

Current research

My current research concerns a newly discovered synthetic lethal relationship between PLK4 inhibition and high expression of TRIM37, an E3 ligase. The gene coding for TRIM37 sits in chromosome 17q, a region that has been found amplified in a subset of breast cancers and in the majority of high-risk neuroblastoma. Cancer cells harbouring the 17q-ter amplification express a high level of TRIM37 and are highly sensitive to PLK4 inhibition. I am interested in identifying key positive and negative regulators involving in the TRIM37-PLK4i synthetic lethality.